

台灣神經內分泌腫瘤學會 2025 年度秋季會

NET Symposium: Stable Precision in the treatment of NeuroEndocrine Tumor

日期：2025/08/23 (星期六) 13:20~17:10

地點：財團法人張榮發基金會國際會議中心 1002 會議室

地址：台北市中正區中山南路 11 號

主辦單位：台灣神經內分泌腫瘤學會(TNET)、台灣介入性膽胰內視鏡學會(TIPES)

協辦單位：台灣諾華股份有限公司、法商益普生股份有限公司台灣分公司、台灣百靈佳殷格翰股份有限公司

報名費：台灣神經內分泌腫瘤學會&台灣介入性膽胰內視鏡學會會員免費  
非會員 1,000 元 (現場繳納)

報到時間：13:00~

| Time        | Topic                                                                                    | Speaker                        | Moderator                           |
|-------------|------------------------------------------------------------------------------------------|--------------------------------|-------------------------------------|
| 13:20~13:30 | Opening remarks                                                                          | <u>陳明晃 理事長</u>                 |                                     |
| 13:30~14:10 | 特別演講：<br>Therapeutic efficacy of SSA on GEP-NET: real-world data                         | <u>黃文冠 醫師</u><br>林口長庚醫院腫瘤科     | <u>吳宜珍 醫師</u><br>高雄醫學大學附設中和紀念醫院胃腸內科 |
| 14:10~14:50 | Beyond Traditional Chemotherapy: A New Era in the Treatment of Neuroendocrine Carcinomas | <u>陳佳宏 醫師</u><br>三軍總醫院腫瘤科      | <u>黃燦龍 名譽理事長</u><br>林口長庚醫院一般外科      |
| 14:50~15:30 | Neuroendocrine Tumors: How Small is Small? Surgical perspective                          | <u>楊卿堯 醫師</u><br>臺大醫院一般外科      | <u>陳建華 醫師</u><br>台北慈濟醫院胃腸肝膽科        |
| 15:30~15:40 | Break                                                                                    |                                |                                     |
| 15:40~16:20 | How to manage GEP/NEN between 1 and 2 cm in size? Surgery or endoscopic resection?       | <u>陳建華 醫師</u><br>台北慈濟醫院胃腸肝膽科   | <u>陳明晃 理事長</u><br>臺北榮民總醫院腫瘤醫學部      |
| 16:20~16:40 | Multifocal small gastric NETs: Case sharing                                              | <u>湯文誠 醫師</u><br>林口長庚醫院腫瘤科     | <u>謝佳訓 醫師</u><br>林口長庚醫院腫瘤科          |
| 16:40~17:00 | Advanced Case Discussion in Pancreatic NET: Rare complication                            | <u>陳明晃 理事長</u><br>臺北榮民總醫院腫瘤醫學部 |                                     |
| 17:00~17:10 | Closing and QA                                                                           | <u>陳建華 醫師</u><br>台北慈濟醫院胃腸肝膽科   |                                     |

學會教育積分：(申請中) 台灣外科醫學會、台灣消化系外科醫學會、台灣內視鏡外科醫學會、台灣內科醫學會、台灣消化系醫學會、台灣消化系內視鏡醫學會、中華民國醫用超音波醫學會、中華民國癌症醫學會

# Curriculum Vitae

**Name:** Wen-Kuan Huang (黃文冠)

**Citizenship:** Taiwan.

**Office Address & Tel No.:** 5, Fu-shin st., Kueishan, Taoyuan, Taiwan, 333, R.O.C, 886-3-3281200 ext. 8825; FAX: 886-3-3272236

**Education:** 1999-2006, MD, School of Medicine, Chung Shan Medical College, Taichung, R.O.C.  
2014-2020, PhD, Karolinska Institutet, Department of oncology-pathology, Stockholm, Sweden.

## Postgraduate Training:

1. Sep. 2007-Jul. 2010: Residentship, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
2. Jul. 2010-Aug. 2012: Fellowship, Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.

## Employment Record:

September 2012-now: Attending Physician, Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan

September 2021-now: Physician scientist, Department of Medical Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan

February 2023-now: Assistant professor, College of Medicine, Chang Gung University, Taoyuan, Taiwan

## Board Certification:

1. Sep. 14, 2005. Physician board, No.:039891
2. Dec. 07, 2010. Internal Physician board, No.:8626
3. Nov. 2012. Medical Oncology board, NO.:101014

## Professional affiliation:

Formosan Medical Association  
The Society of Internal Medicine  
Taiwan Oncology Society

**Research of Interest:** cancer metabolism, immune microenvironment, DNA damage repair

## Grants

1. CMRPG3B0951 肝膿瘍及反覆化膿性膽道炎與膽道癌的關係及預後 2012/9/1~2013/8/31 (PI)
2. CMRPG3D0521 免疫組織化學染色(IHC)與 DNA 定序對於亞洲族群原發性及轉移性惡性黑色素瘤特定基因 BRAF V600E 突變的比較分析 2014/2/1~2015/1/31 (PI)
3. 103-2314-B-182A-087 - (國科會)探討染色體不穩定作為新標靶治療肢端型黑色素瘤的研究 20140801~20151031 (co-PI)
4. 104-2314-B-182 -009 - (國科會)熊去氧膽酸使用與大腸直腸癌發生的關係：全國性世代研究

20150801~20161031 (co-PI)

5.105-2314-B-182 -025 -MY2 (國科會)癌症病人罹患情感性疾患的發生率、危險因子與死亡風險-全國性研究 20160801~20180731(co-PI)

6.107-2314-B-182 -050 - (國科會)探討前列腺癌病人接受荷爾蒙治療的不良作用 20180801~20190731 (co-PI)

7.108-2314-B-182A-063 - (國科會)微小核糖核酸介導胃腸道基質瘤 imatinib 抗藥性經由調控粒線體代謝研究 2019/08/01~ 2020/07/31 (PI)

8.CMRPG3K172 (二年期) 胃腸道基質瘤 miR-483-3p 調控有氧磷酸化及 imatinib 藥物反應透過抑制琥珀酸脫氫酵素機轉研究 2020/10/1~2022/9/30 (PI)

9.108-2314-B-182A-057- (國科會) 探討雄性激素剝奪治療對於小鼠血管發炎及後續動脈斑塊形成的影響 20190801~ 20221231 (co-PI)

10. 109-2314-B-182 -035-(國科會) 氟尿酸-輔助化療對接受手術治療大腸直腸癌患者的心臟毒性：台灣全國性世代研究 20200801~ 20211031 (co-PI)

11. 111-2314-B-182 -016-(國科會) 糖尿病病人使用 pioglitazone 對日後罹患癌症的風險：從巢式病例對照研究到依時間改變暴露的世代研究 20220801~ 20230731(co-PI)

12.111-2314-B-182A-031- (國科會)胃癌微衛星不穩定狀態與腫瘤免疫微環境特徵分析 2022/08/01 ~2023/07/31 (PI)

13. CMRPG3M2101 TIGIT 抗體結合 PD-1 抗體在微衛星不穩定胃癌療效研究 2022/12/1-2023/11/30 (PI)

14. CMRPG3N0481(三年期) HIF1-alpha 與 circCSPF6/CPSF6 相互作用促進胰腺癌生長 2023/07/01-2026/6/30 (PI)

15. 113-2314-B-182 -028 - (國科會) 建立肝內膽道癌小鼠模型探索免疫微環境與免疫反應標誌物 (PI)

## Publications

1.**Huang WK**, Tang YJ, Wu CE, Hou MM, Hsu HC, Su PJ, Chiang NJ, Chen SC, Yeh CN, Chen JS, Chen MH, Hsieh CH, Chou WC. Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer. *Oncologist*. 2024 Nov 20 (2023):4.8, ONCOLOGY|Q1|70/322 (21.7%)

2. Chen Y, Su Y, Cao X, Siavelis I, Leo IR, Zeng J, Tsagkozis P, Hesla AC, Papakonstantinou A, Liu X, **Huang WK**, Zhao B, Haglund C, Ehnman M, Johansson H, Lin Y, Lehtiö J, Zhang Y, Larsson O, Li X, de Flon FH. Molecular Profiling Defines Three Subtypes of Synovial Sarcoma. *Adv Sci (Weinh)*. 2024 Sep 10. IF (2023):14.3, NANOSCIENCE& NANOTECHNOLOGY |Q1|12/140 (8.5%)

3. **Huang WK**, Zhang Z, Chen J, Lin J, Wang Y, Yan X, Zhang W, Ning S, & You Q. Coordination engineering of FeCo dual single-atom nanozymes with photothermal-enhanced

- cascaded catalysis for efficient pancreatic cancer immunotherapy. *Chemical Engineering Journal*. 2024, Sep; 496, 154203. IF (2023):13.1, ENGINEERING, ENVIRONMENTAL|Q1|3/81 (3.7%)
4. Hung LJ, Huang CY, Tung KC, Chen JS, Huang WK, Hsu CC, Fang YF, Wang CL, Liu PC, Yeh KY, Chang PH, Chang JW, Lin YC, Huang SF, Chou WC. Comprehensive genomic profiling in multiple cancer types: A comparative analysis of the National Biobank Consortium of Taiwan and clinical practice cohorts. *J Formos Med Assoc*. 2024 Sep 6:S0929-6646(24)00405-4. IF (2023):2.6, MEDICINE, GENERAL & INTERNAL|Q1|70/325 (21.5%)
  5. Chen DY, Chang SH, Huang WK, Hsieh IC, See LC. The cold temperature associated with new-onset heart failure after incorporating dynamic status of multimorbidity: nationwide cohort, Taiwan 2012-2019. *Eur J Prev Cardiol*. 2024 Aug 23:zwae260. IF(2023):8.4, CARDIAC & CARDIOVASCULAR SYSTEMS|Q1|16/220 (7.2%)
  6. Huang WK, Hung YL, Tsai CY, Wu CE, Chou WC, Hsu JT, Yeh TS, Chen JS, Wang SY, Yeh CN. Efficacy of first-line combination therapies versus gemcitabine monotherapy for advanced pancreatic cancer: a systematic review and network meta-analysis. *Am J Cancer Res*. 2024 Jul 15;14(7):3523-3532. IF(2023):3.6, ONCOLOGY|Q2|106/322 (32.9%)
  7. Chen CP, Lin SF, Yeh CN, Huang WK, Pan YR, Hsiao YT, Lo CH, Wu CE. Synergistic effects of the combination of trametinib and alpelisib in anaplastic thyroid cancer with BRAF and PI3KCA co-mutations. *Heliyon*. 2024 Mar 30;10(7):e29055. IF(2023):3.4, MULTIDISCIPLINARY SCIENCES|Q1|28/134 (20.8%)
  8. Chang PH, Chen HY, Chang YS, Su PJ, Huang WK, Lin CF, Hsieh JC, Wu CT. Effect of Clinical Complete Remission Following Neoadjuvant Pembrolizumab or Chemotherapy in Bladder-Preservation Strategy in Patients with Muscle-Invasive Bladder Cancer Declining Definitive Local Therapy. *Cancers(Basel)*. 2024 Feb 23;16(5):894. IF(2023):4.5, ONCOLOGY|Q1|78/322 (24.2%)
  9. Yu JH, Li PR, Chen DY, Huang WK, See LC. Mortality after major bleeding in Asian atrial fibrillation patients receiving different direct oral anticoagulants: a nationwide, propensity score study. *Sci Rep*. 2024 Feb 27;14(1):4771. IF(2023):3.8, MULTIDISCIPLINARY SCIENCES|Q1|25/134 (18.6%)
  10. Chou TT, Hsu HC, Twu CW, Huang WK, Huang HM, Weng SH, Chen MC. Prevalence of Obstructive Sleep Apnea Using Home Sleep Test in Taiwan During the Coronavirus Disease Pandemic. *Nat Sci Sleep*. 2023 Dec 22;15:1107-1116. IF(2023):3.0, NEUROSCIENCES |Q2|140/310
  11. Pan YR, Lai JC, Huang WK, Peng PH, Jung SM, Lin SH, Chen CP, Wu CE, Hung TH, Yu AL, Wu KJ, Yeh CN. PLK1 and its substrate MISP facilitate intrahepatic cholangiocarcinoma progression by promoting lymphatic invasion and impairing E-cadherin adherens junctions. *Cancer Gene Ther*. 2024 Feb;31(2):322-333. IF(2023): 4.8, ONCOLOGY|Q1|70/322 (21.7%)
  12. Huang WK, Hsu HC, Yang TS, Lu CW, Pan YR, Wu CE, Chung WH, Hung SI, Yeh CN. Zinc supplementation decreased incidence of grade  $\geq 2$  hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial. *Eur J Cancer*. 2023 Dec;195:113286. IF(2023):7.6, ONCOLOGY|Q1|38/322 (11.8%)

13. **Huang WK**, Hsu HC, Yang TS, Lu CW, Pan YR, Wu CE, Chung WH, Hung SI, Yeh CN. Zinc supplementation decreased incidence of grade  $\geq 2$  hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial. *J Am Acad Dermatol*. 2024 Feb;90(2):368-369. IF(2023):12.8, DERMATOLOGY|Q1|1/94 (1%)
14. Chen DY, Lee CH, Tsai ML, Hsieh MJ, Chuang CK, Pang ST, Chen SW, Tseng CN, Chang SH, Chu PH, Hsieh IC, Wu VC, **Huang WK\***. Cancer Therapy-Related Cardiac Dysfunction in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy. *J Am Heart Assoc*. 2023 Oct 3;12(19):e030447. IF(2023): 5.0, CARDIAC&CARDIOVASCULAR SYSTEMS|Q1|39/220 (17.7%)
15. Yu JH, Hsieh SH, Chen CH, **Huang WK**. Comparison of the safety, effectiveness, and usability of swab robot vs. manual nasopharyngeal specimen collection. *Heliyon*. 2023 Oct 13;9(10):e20757. IF(2023):3.4, MULTIDISCIPLINARY SCIENCES|Q1|28/134 (20.8%)
16. Chen CP, Yeh CN, Pan YR, **Huang WK**, Hsiao YT, Lo CH, Wu CE. Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer. *Biomed Pharmacother*. 2023 Oct;166:115389. IF(2023): 6.9, PHARMACOLOGY & PHARMACY|Q1|15/354 (4.2%)
17. Chang JW, Huang CJ, **Huang WK**, Wang YC, Hsieh JJ, Chang YY, Huang YL, Wu CL, Wang YH, Chen SJ, Tan KT, Chen CP, Wu CE. Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma. *Clin Transl Immunology*. 2023 Aug 29;12(8):e1465. IF(2023):4.6, IMMUNOLOGY|Q2|56/181 (30.9%)
18. Pan YR, Wu CE, Jung SM, Huang SC, Lin SH, Chou WC, Chang YC, Chen MH, Hung TH, Yu AL, **Huang WK\***, Yeh CN. Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation. *Int J Biol Sci*. 2023 May 21;19(9):2772-2786. IF(2023):8.2, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|31/313 (9.9%)
19. Tseng CN, Chen DY, Chang SH, Huang WK, Hsieh MJ, See LC. Ambient Temperature Effect on Acute Myocardial Infarction by Risk Factors: Daily Data From 2000 to 2017, Taiwan. *JACC Asia*. 2023 Mar 14;3(2):228-238.
20. Yeh CN, **Huang WK**, Lu CW, Chen CP, Lin SH, Pan YR, Wu CE. A Potential Association of Zinc Deficiency and Tyrosine Kinase Inhibitor-Induced Hand-Foot Skin Reaction. *Biol Trace Elem Res*. 2023 Dec;201(12):5540-5545.
21. **Huang WK**, Huang SC, Chen CM, Lin PH, Wu CE, Chuang CK, Yeh CN. Marked Response to Larotrectinib in Pelvic Spindle Cell Sarcoma With Concurrent TPM3-NTRK1 Fusion and CDK4/MDM2 Amplification: A Case Report. *JCO Precis Oncol*. 2023 Jan;7:e2200528. IF(2023): 5.3, ONCOLOGY|Q1|61/322 (18.9%)
22. Chen HK, Su PJ, Wang YL, Chang KC, Su YL, Chang PH, Kuan FC, Hsieh CH, Kuo YC, Sheng TW, Chang CF, Yu SM, **Huang WK**, Lin YC, Tsan DL, Yu KJ, Lin PH, Chen HY, Chang YH, Pang ST, Chuang CK, Lai EC. Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-

resistant prostate cancer. *Int J Cancer*. 2023 Mar 15;152(6):1191-1201. IF(2023): 5.7, ONCOLOGY|Q1|54/322 (16.7%)

23. Pan YR, Wu CE, Huang WK, Chen MH, Lan KH, Yeh CN. Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma. *Front Immunol*. 2022 Oct 20;13:982196. IF(2023): 5.7, IMMUNOLOGY|Q1|38/181 (20.9%)

24. Lin LC, Huang WK, Yen CC, Yang CY, Sung MT, Wong NSM, Chua DTT, Lee SWM, Chen JS, Yeh CN. Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience. *Front Oncol*. 2022 Oct 13;12:1028118. IF(2023): 3.5, ONCOLOGY|Q2|107/322 (33.2%)

25. Lun R, Roy DC, Hao Y, Deka R, Huang WK, Navi BB, Siegal DM, Ramsay T, Fergusson D, Shorr R, Dowlathshahi D. Incidence of stroke in the first year after diagnosis of cancer-A systematic review and meta-analysis. *Front Neurol*. 2022 Sep 20;13:966190.

26. Huang WK, Ho WP, Hsu HC, Chang SH, Chen DY, Chou WC, Chang PH, Chen JS, Yang TS, See LC. Risk of cardiovascular disease among different fluoropyrimidine-based chemotherapy regimens as adjuvant treatment for resected colorectal cancer. *Front Cardiovasc Med*. 2022 Aug 3;9:880956. IF(2023): 2.8, CARDIAC&CARDIOVASCULAR SYSTEMS|Q2|79/220 (35%)

27. Huang WK, Wu CE, Wang SY, Chang CF, Chou WC, Chen JS, Yeh CN. Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges. *Curr Treat Options Oncol*. 2022 Sep;23(9):1303-1319. IF(2023):3.8, ONCOLOGY|Q2|102/322 (31.6%)

**27.** Wu CE, Chen CP, Huang WK, Pan YR, Aptullahoglu E, Yeh CN, Lunec J. p53 as a biomarker and potential target in gastrointestinal stromal tumors. *Front Oncol*. 2022 Jul 29;12:872202. . IF(2023): 3.5, ONCOLOGY|Q2|107/322 (33.2%)

28. Chang PH, Lee CH, Wu TM, Yeh KY, Wang HM, Huang WK, Chan SC, Chou WC, Kuan FC, Kuo HC, Kuo YC, Hu CC, Hsieh JC. Association of early changes of circulating cancer stem-like cells with survival among patients with metastatic breast cancer. *Ther Adv Med Oncol*. 2022 Jul 15;14:17588359221110182. IF(2023): 4.3, ONCOLOGY|Q2|88/322 (27.3%)

29. Lin LC, Huang WK, Yen CC, Yang CY, Sung MT, Wong NS, Chua DTT, Lee SWM, Chen JS, Yeh CN. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience. *Front Oncol*. 2022 Jun 29;12:883399. IF(2023): 3.5, ONCOLOGY|Q2|107/322 (33.2%)

30. Chen DY, Liu JR, Tseng CN, Hsieh MJ, Chuang CK, Pang ST, Chen SW, Hsieh IC, Chu PH, Chen JS, Wen-Cheng Chang J, Huang WK\*, See LC. Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies. *JACC CardioOncol*. 2022 Jun 21;4(2):223-234. IF(2023): 12.0, ONCOLOGY|Q1|22/322 (6.8%)

31. Wang C, Wan H, Zhang H, Yang B, Huang WK, Sun W. Characterization of Ligand-Receptor Pair in Bladder Cancer Develops a Validated Scoring Model for Prognosis and Treatment Response. *Front Cell Dev Biol*. 2022 Jun 17;10:915798. IF(2023):4.6, DEVELOPMENTAL BIOLOGY|Q1|5/39 (12.8%)

32. Chen Y, You S, Li J, Zhang Y, Kokaraki G, Epstein E, Carlson J, Huang WK\*, Haglund F.

Follicular Helper T-Cell-Based Classification of Endometrial Cancer Promotes Precise Checkpoint Immunotherapy and Provides Prognostic Stratification. *Front Immunol.* 2022 Jan 7;12:788959. IF(2023): 5.7, IMMUNOLOGY|Q1|38/181 (20.9%)

33. Chen DY, Chen CC, Tseng CN, Chen SW, Chang SH, Huang WK, Wen MS, Hsieh MJ, Hsieh IC. Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study. *EClinicalMedicine.* 2021 Oct 8;41:101149. IF(2023): 9.6, MEDICINE, GENERAL & INTERNAL|Q1|12/325 (3.6%)

34. Jin X, Yan J, Chen C, Chen Y, Huang WK. Integrated Analysis of Copy Number Variation, Microsatellite Instability, and Tumor Mutation Burden Identifies an 11-Gene Signature Predicting Survival in Breast Cancer. *Front Cell Dev Biol.* 2021 Sep 28;9:721505. IF(2023):4.6, DEVELOPMENTAL BIOLOGY|Q1|5/39 (12.8%)

35. Huang WK, Shi H, Akçakaya P, Zeljic K, Gangaev A, Caramuta S, Yeh CN, Bränström R, Larsson C, Lui WO. Imatinib Regulates miR-483-3p and Mitochondrial Respiratory Complexes in Gastrointestinal Stromal Tumors. *Int J Mol Sci.* 2021 Sep 30;22(19):10600. IF(2023):8.2, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|31/313 (9.9%)

36. Liu CH, Sung PS, Li YR, Huang WK, Lee TW, Huang CC, Lee TH, Chen TH, Wei YC. Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study. *PLoS Med.* 2021 Jul 19;18(7):e1003707. IF(2023):10.5, MEDICINE, GENERAL & INTERNAL|Q1|10/325 (3%)

37. Huang WK, Hsu HC, Chang SH, Chou WC, Chang PH, Chiang SF, Chang JW, Chen JS, Yang TS, See LC. Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer: A Controlled Interrupted Time Series Analysis. *Front Pharmacol.* 2021 Jun 29;12:693009. IF(2023): 4.4, PHARMACOLOGY & PHARMACY|Q1|65/354 (18.3%)

38. Wu CE, Huang WK, Chou WC, Hsieh CH, Chang JW, Lin CY, Yeh CN, Chen JS. Establishment of a Pretreatment Nomogram to Predict the 6-Month Mortality Rate of Patients with Advanced Biliary Tract Cancers Undergoing Gemcitabine-Based Chemotherapy. *Cancers (Basel).* 2021 Jun 23;13(13):3139. IF(2023):4.5, ONCOLOGY|Q1|78/322 (24%)

39. Chen DY, Su PJ, See LC, Liu JR, Chuang CK, Pang ST, Tseng CN, Chen SW, Hsieh IC, Chu PH, Lin YC, Hsu CL, Chang JW, Lin MS, Pang JS, Hsieh MJ, Huang WK\*. Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study. *Prostate.* 2021 Sep;81(12):902-912. IF(2023): 2.7 UROLOGY&NEPHROLOGY|Q2| 36/126 (28.5%)

40. Chang YR, Huang WK, Wang SY, Wu CE, Chen JS, Yeh CN. A Nomogram Predicting Progression Free Survival in Patients with Gastrointestinal Stromal Tumor Receiving Sunitinib: Incorporating Pre-Treatment and Post-Treatment Parameters. *Cancers (Basel).* 2021 May 25;13(11):2587. IF(2023):4.5, ONCOLOGY|Q1|78/322 (24%)

41. Huang WK, Chen Y, Su H, Chen TY, Gao J, Liu Y, Yeh CN, Li S. ARHGAP25 Inhibits

Pancreatic Adenocarcinoma Growth by Suppressing Glycolysis via AKT/mTOR Pathway. *Int J Biol Sci.* 2021 Apr 24;17(7):1808-1820. IF(2023):8.2, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|31/313 (9.9%)

42. Chen DY, Tseng CN, Hsieh MJ, Lan WC, Chuang CK, Pang ST, Chen SW, Chen TH, Chang SH, Hsieh IC, Chu PH, Wen MS, Chen JS, Chang JW, See LC, Huang WK\*. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism. *JAMA Netw Open.* 2021 Feb 1;4(2):e2036304. IF(2023): 10.5, MEDICINE, GENERAL & INTERNAL|Q1|10/325 (3%)

43. Pan YR, Wu CE, Chen MH, Huang WK, Shih HJ, Lan KL, Yeh CN. Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model. *Vaccines (Basel).* 2020 Nov 24;8(4):703. IF(2023): 5.2, MEDICINE, RESEARCH & EXPERIMENTAL|Q1|39/189 (1.5%)

44. Wu CE, Yeh DW, Pan YR, Huang WK, Chen MH, Chang JW, Chen JS, Wang YC, Yeh CN. Chromosomal Instability May Not Be a Predictor for Immune Checkpoint Inhibitors from a Comprehensive Bioinformatics Analysis. *Life (Basel).* 2020 Nov 8;10(11):276.

45. Huang WK, Yeh CN. The Emerging Role of MicroRNAs in Regulating the Drug Response of Cholangiocarcinoma. *Biomolecules.* 2020 Sep 30;10(10):1396. IF(2023):4.8, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|67/313 (21.4%)

46. Huang WK, Liu CH, Pang ST, Liu JR, Chang JW, Liaw CC, Hsu CL, Lin YC, See LC. Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan. *JAMA Netw Open.* 2020 Aug 3;3(8):e2015189. IF(2023):10.5, MEDICINE, GENERAL & INTERNAL|Q1|10/325 (3%)

47. Huang WK, Gao J, Chen Z, Shi H, Yuan J, Cui HL, Yeh CN, Bränström R, Larsson C, Li S, Lui WO. Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor. *Cells.* 2020 May 26;9(6):1333. IF(2023): 5.1, CELL BIOLOGY|Q2|63/205 (30.7%)

48. Huang WK, Chang SH, Hsu HC, Chou WC, Yang TS, Chen JS, Chang JW, Lin YC, Kuo CF, See LC. Postdiagnostic metformin use and survival of patients with colorectal cancer: A Nationwide cohort study. *Int J Cancer.* 2020 Oct 1;147(7):1904-1916. IF(2023): 5.7, ONCOLOGY|Q1|54/322 (16.7%)

49. Lee CH, Hsieh JC, Wu TM, Yeh TS, Wang HM, Lin YC, Chen JS, Lee CL, Huang WK, Hung TM, Yen TT, Chan SC, Chou WC, Kuan FC, Hu CC, Chang PH. Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer. *BMC Cancer.* 2019 Dec 2;19(1):1167. IF(2023):3.4, ONCOLOGY|Q2|110/322 (34.1%)

50. Chen DY, Huang WK, Chien-Chia Wu V, Chang WC, Chen JS, Chuang CK, Chu PH. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. *J Formos Med Assoc.* 2020 Oct;119(10):1461-1475. IF(2023): 2.6, MEDICINE, GENERAL & INTERNAL|Q1|70/325 (21.5%)

51. Chang PH, Wu MH, Liu SY, Wang HM, Huang WK, Liao CT, Yen TC, Ng SH, Chen JS, Lin



- YC, Lin HC, Hsieh JC. The Prognostic Roles of Pretreatment Circulating Tumor Cells, Circulating Cancer Stem-Like Cells, and Programmed Cell Death-1 Expression on Peripheral Lymphocytes in Patients with Initially Unresectable, Recurrent or Metastatic Head and Neck Cancer: An Exploratory Study of Three Biomarkers in One-time Blood Drawing. *Cancers (Basel)*. 2019 Apr 15;11(4):540. IF(2023):4.5, ONCOLOGY|Q1|78/322 (24%)
52. Hou CH, Lee JS, Lin KK, Chang SH, Huang WK, Kuo CF, See LC. Endophthalmitis Incidence of Cancer Patients After Cataract Surgery: A Nationwide Matched Cohort Study in Taiwan. *Am J Ophthalmol*. 2019 Mar;199:246-254. IF(2023):4.1, OPHTHALMOLOGY|Q1| 10/95 (10.5%)
53. Huang WK, Akçakaya P, Gangaev A, Lee L, Zeljic K, Hajeri P, Berglund E, Ghaderi M, Åhlén J, Bränström R, Larsson C, Lui WO. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors. *Exp Cell Res*. 2018 Oct 1;371(1):287-296. IF(2023):3.3, ONCOLOGY|Q2|118/322 (36.6%)
54. Huang WK, Juang YY, Chung CC, Chang SH, Chang JW, Lin YC, Wang HM, Chang HK, Chen JS, Tsai CS, Yu KH, Kuo CF, See LC. Timing and risk of mood disorders requiring psychotropics in long-term survivors of adult cancers: A nationwide cohort study. *J Affect Disord*. 2018 Aug 15;236:80-87. IF(2023):4.9, PSYCHIATRY|Q1|38/276 (13.7%) IF(2023):8.2, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|31/313 (9.9%)
55. Chou WC, Wu MH, Chang PH, Hsu HC, Chang GJ, Huang WK, Wu CE, Hsieh JC. A Prognostic Model Based on Circulating Tumour Cells is Useful for Identifying the Poorest Survival Outcome in Patients with Metastatic Colorectal Cancer. *Int J Biol Sci*. 2018 Jan 12;14(2):137-146. IF(2023):8.2, BIOCHEMISTRY & MOLECULAR BIOLOGY|Q1|31/313 (9.9%)
56. Kao WH, Kuo CF, Chou IJ, See LC, Huang WK, Chiou MJ, Zhang W, Doherty M, Wang CC, Hsu JT, Chen HH, Hong JH. Prostate-selective  $\alpha$  antagonists increase fracture risk in prostate cancer patients with and without a history of androgen deprivation therapy: a nationwide population-based study. *Oncotarget*. 2018 Jan 2;9(4):5263-5273.
57. Chen DY, See LC, Liu JR, Chuang CK, Pang ST, Hsieh IC, Wen MS, Chen TH, Lin YC, Liaw CC, Hsu CL, Chang JW, Kuo CF, Huang WK\*. Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study. *J Clin Oncol*. 2017 Nov 10;35(32):3697-3705. IF(2023): 42.1, ONCOLOGY|Q1|6/322 (1.8%)
58. Su PJ, Wu MH, Wang HM, Lee CL, Huang WK, Wu CE, Chang HK, Chao YK, Tseng CK, Chiu TK, Lin NM, Ye SR, Lee JY, Hsieh CH. Circulating Tumour Cells as an Independent Prognostic Factor in Patients with Advanced Oesophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy. *Sci Rep*. 2016 Aug 17;6:31423.
59. Huang WK, Kuo TT, Wu CE, Cheng HY, Hsieh CH, Hsieh JJ, Shen YC, Hou MM, Hsu T, Chang JW. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan. *Asia Pac J Clin Oncol*. 2016 Dec;12(4):403-408.
60. Yu KH, Kuo CF, Huang LH, Huang WK, See LC. Cancer Risk in Patients With Inflammatory

Systemic Autoimmune Rheumatic Diseases: A Nationwide Population-Based Dynamic Cohort Study in Taiwan. *Medicine (Baltimore)*. 2016 May;95(18):e3540.

61. **Huang WK**, Hsu HC, Liu JR, Yang TS, Chen JS, Chang JW, Lin YC, Yu KH, Kuo CF, See LC. The Association of Ursodeoxycholic Acid Use With Colorectal Cancer Risk: A Nationwide Cohort Study. *Medicine (Baltimore)*. 2016 Mar;95(11):e2980.

62. Huang CY, Lu CH, Yang CK, Hsu HC, Kuo YC, **Huang WK**, Chen JS, Lin YC, Chia-Yen H, Shen WC, Chang PH, Yeh KY, Hung YS, Chou WC. A Simple Risk Model to Predict Survival in Patients With Carcinoma of Unknown Primary Origin. *Medicine (Baltimore)*. 2015 Nov;94(47):e2135.

63. **Huang WK**, Tu HT, See LC. Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence. *Curr Pharm Des*. 2015;21(35):5108-15.

64. Wu CF, Wang HM, **Huang WK**, Chang JW. Efficacy and safety of bio-chemotherapy with dacarbazine plus interleukin-2 in patients with unresectable malignant melanoma. *Asia Pac J Clin Oncol*. 2015 Dec;11(4):314-8.

68. Lin CY, **Huang WK**, Chung FT, Chang HK. Prognostic factors in cancer patients with symptomatic pituitary metastasis: a clinical case study. *Anticancer Res*. 2015 Feb;35(2):983-7.

69. Wu CE, Wang CW, **Huang WK**, Yang CT, Wu YC, Hou MM, Hsieh CH, Hsieh JJ, Cheng HY, Hsu T, Chang JW. Cytoplasmic and nuclear parathyroid hormone-related proteins are opposing prognostic factors in patients with non-small-cell lung cancer who have undergone curative resection. *Jpn J Clin Oncol*. 2015 Mar;45(3):267-73.

70. **Huang WK**, Kuo YC, Tsang NM, Hsu HC, Shen WC, Chou WC, Yang TS, Chen JS. Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer. *Anticancer Res*. 2014 Nov;34(11):6755-61.

71. **Huang WK**, Chiou MJ, Kuo CF, Lin YC, Yu KH, See LC. No overall increased risk of cancer in patients with rheumatoid arthritis: a nationwide dynamic cohort study in Taiwan. *Rheumatol Int*. 2014 Oct;34(10):1379-86.

72. **Huang WK**, Lin YC, Chiou MJ, Yang TS, Chang JW, Yu KH, Kuo CF, See LC. Pyogenic liver abscess as a warning sign for primary liver cancer: a nationwide population-based study. *Asian Pac J Cancer Prev*. 2013;14(8):4727-31.

73. **Huang WK**, Chiou MJ, Yu KH, Lin YC, Yang TS, Chen JS, Kuo CF, See LC. The association between low-dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study. *Aliment Pharmacol Ther*. 2013 Aug;38(4):432-9.

74. **Huang WK**, Liaw CC, Pang ST, Chuang CK, Chiang YJ, Wu CT, Chang YH, Wang HM, Lin YC, Hsieh JJ, Ou LY, Tsai SI, Yang CH, Yang CT, Chang JW. Everolimus in metastatic renal cell carcinoma: preliminary experience from Chang Gung Memorial Hospital. *Chang Gung Med J*. 2012 Sep-Oct;35(5):402-7.

75. **Huang WK**, Chang JW, See LC, Tu HT, Chen JS, Liaw CC, Lin YC, Yang TS. Higher rate of colorectal cancer among patients with pyogenic liver abscess with *Klebsiella pneumoniae* than those without: an 11-year follow-up study. *Colorectal Dis*. 2012 Dec;14(12):e794-801.

# CURRICULUM VITAE

**Chen JH, M.D., Ph.D.**

**Attending Physician,**

Division of Hematology and Oncology,

Department of Internal Medicine,

Tri-Service General Hospital (TSGH),

**professor,**

School of Medicine, TSGH, NDMC.

**Office Address:**

Division of Hematology and Oncology

Department of Internal Medicine

Tri-Service General Hospital

National Defense Medical Center

No. 325, Sec. 2, Cheng-Kung Road, NeiHu, Taipei 114, Taiwan, R.O.C.

Tel.: 886-2-87927208

Fax: 886-2-87927209

E-mail: [ndmc\\_tw.tw@yahoo.com.tw](mailto:ndmc_tw.tw@yahoo.com.tw)

**Date of Birth:** Nov 6, 1978

**Citizenship:** Taiwan, Republic of China (R.O.C.)

**Education:**

1998-2004 National Defense Medical Center, M.D. (Doctor of Medicine)

2012-2021 Graduate Institute of Clinical Medicine, Taipei Medical  
University(Ph.D)

**Experiences:**

2006-2010 Resident, Department of Medicine, TSGH, NDMC.

2010-2011 Chief Resident, Department of Medicine, TSGH, NDMC

2016-2019 Assistant Professor, School of Medicine, TSGH, NDMC.

2019-2024 Associate professor, School of Medicine, TSGH, NDMC.

2011- Attending Physician, Division of Hematology and Oncology,  
Department of Medicine, TSGH, NDMC

2025- professor, School of Medicine, TSGH, NDMC.

**Memberships:**

The Society of Internal Medicine.

The Society of Hematology.

The Society of Bone Marrow Transplantation.  
The Society of Oncology  
The Society of Hospice and Palliative Medicine.  
The Breast Cancer Society of Taiwan  
Taiwan Head and Neck Society

## **PUBLICATIONS:**

### **Image**

1. **Chen JH**, Wu ST, Chang WK. Which one is the urinary bladder? Ann Saudi Med. 2009 Sep-Oct;29(5):410-1.(SCI)
2. **Chen JH**, Chao TY, Perng WC. Strongyloid stercoralis infection of skin and lung. QJM. 2010 Mar;103(3):199-200. (SCI)
3. **Chen JH**, Chen KY, Chang WK. Intestinal obstruction induced by phytobezoars. CMAJ. 2010 Nov 23;182(17):E797. (SCI)
4. **Chen JH**, Chen KY, Lin SH. Gout or not in uraemic patient. Acta Clin Belg. 2010 Mar-Apr;65(2):136-7. (SCI)
5. **Chen JH**, Wu ST, Wu CC. Autosomal dominant polycystic kidney disease with cystic haemorrhage and infection. Acta Clin Belg. 2010 Nov-Dec;65(6):446-7. (SCI)
6. **Chen JH**, Chen KY. Acute sciatica in a patient with herpes zoster infection. Acta Clin Belg. 2011 Jan-Feb;66(1):70-1. (SCI)
7. Huang TC, Chen JH, Wu YY. Burden of Multiple Myeloma in Taiwan. JAMA Oncol. 2019 Jan 1;5(1):116.
8. Lin HH, Lin YC, **Chen JH**, Wang YC. Relapsed multiple myeloma with gastric and pancreatic extramedullary plasmacytomas. J Formos Med Assoc. 2023 Apr;122(4):355-357.

### **Case report and challenging case**

1. **Chen JH**, Tsai WC, Ho CL. Secondary nodal marginal zone B cell lymphoma arising in primary mixed cellularity subtype of Hodgkin's lymphoma. Ann Hematol. 2009 May;88(5):501-3. (SCI)
2. **Chen JH**, Chang PY, Yao NS. Gemcitabine plus vinorelbine as an effective salvage chemotherapeutic regimen in cisplatin-refractory germ cell tumor. South Med J. South Med J. 2009 May;102(5):546-8.(SCI)
3. **Chen JH**, Chang PY, Ho CL, Chen PJ. Radiofrequency ablation as a palliative treatment of primary liver sarcoma in an inoperable patient with hepatitis C virus-related cirrhosis. Onkologie. 2009 Sep;32(8-9):509-12.(SCI)
4. Hsiao PJ, Kuo SM, **Chen JH**, Lin HF, Chu PL, Lin SH, Ho CL. Acute

- myelogenous leukemia and acute leukemic appendicitis: a case report. *World J Gastroenterol*. 2009 Nov 28;15(44):5624-5.(SCI)
5. **Chen JH**, Chang PY, Yao NS. Gemcitabine plus vinorelbine as an effective salvage chemotherapeutic regimen in advanced Hodgkin lymphoma. *Hematol Oncol Stem Cell Ther*. 2009;2(2):371-2. (SCI)
  6. **Chen JH**, Ho CL, Chao TY, Chang WK. Febrile Neutropenia after Sunitinib in Patient with Advanced Hepatocellular Carcinoma. *Journal of the Chinese oncology society*
  7. Chen JL, Chen KY, Lin CJ, Perng WC, **Chen JH**. Carcinosarcoma of the pleura and lung metastasized from a poorly differentiated squamous cell carcinoma of the esophagus. *Hematol Oncol Stem Cell Ther*. 2010;3(1):47-50. (SCI)
  8. **Chen JH**, Chang PY, Ho CL, Chen YC, Kao WY. Retroperitoneal metastatic adenocarcinoma complicated with necrotizing fasciitis of the thigh in a patient with advanced rectal colon cancer. *Case Rep Oncol*. 2010 Aug 12;3(2):304-9. (SCI)
  9. Tang WH, **Chen JH**, Ye RH, Ho CL. Near Total Regression of Diffuse Brain Metastases in Adenocarcinoma of the Lung with an EGFR Exon 19 Mutation: A Case Report and Review of the Literature. *Case Rep Oncol*. 2011 Sep;4(3):445-51. (SCI)
  10. **Chen JH**, Ho CL, Chen YC, Chao TY, Kao WY, He CT. Prednisolone for Therapy of Advanced Gastrointestinal Stromal Tumor - Induced Hypoglycemia. *J. Cancer Res. Pract.*
  11. Tsai HF, Kao WY, Hueng DY, **Chen JH**. Mutual Use of the Experience of Hospice Care and Organ Donation. *Taiwan Journal of Hospice Palliative Care*
  12. **Chen JH**, Chang WK, Chang PY. Cytomegalovirus-related Gastritis in a Patient with Solid and Papillary Epithelial Neoplasm of Pancreas. *J. Cancer Res. Pract.* 29(4)
  13. Lai SW, **Chen JH**, Kao WY. Acute hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency complicated by Ginkgo biloba. *Acta Haematol*. 2013;130(4):288-90. (SCI)
  14. **Chen JH**, Chen KY, Hueng DY, Jin JS. Secondary pulmonary conventional chordoma arising from primary sarcomatoid chordoma of the sacrum: A case report. *Oncol Lett*. 2014 Jul;8(1):208-210. (SCI)
  15. Hsu SN, **Chen JH**, Kao WY. Allogeneic Hematopoietic Stem Cell Transplantation as First-line Treatment Option in a Severe Aplastic Anemia Patient without Matched Related Donors. *Oncol Lett*. 2014 Oct;8(4):1831-1833. (SCI)
  16. Chen YG, **Chen JH**, Huang TC. Tension pneumoperitoneum in a lung cancer patient with intestinal metastases. *J Emerg Med*. 2015 Jan;48(1):e23-4. (SCI)

17. Lai SW, Huang TC, **Chen JH**, Wu YY, Chang PY. Dasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: A case report. *Oncol Lett*. 2015 Apr;9(4):1957-1961. (SCI)
18. Tsai CC, **Chen JH**, Wang YC, Chang FY. Re-activation of pulmonary tuberculosis during anti-programmed death-1 (PD-1) treatment. *QJM*. 2019 Jan 1;112(1):41-42.
19. Hu CC, Wang CW, **Chen JH**. Application of Color Doppler Ultrasound to Evaluate Chemotherapeutic Effect on Primary Thyroid Lymphoma. *J Med Ultrasound*. 2020 May 25;29(1):60-63.
20. Lin HH, Lin YC, **Chen JH**, Wang YC. Relapsed multiple myeloma with gastric and pancreatic extramedullary plasmacytomas. *J Formos Med Assoc*. 2023 Jan 22:S0929-6646(23)00001-3.

### **Original article**

1. **Chen JH**, Chen KY, Ma HI, Yu CP, Nieh S, Lee HS, Jin JS. Cortactin, Fascin, and Survivin Expression Associated with Clinicopathological Parameters in Brain Gliosarcoma. *Chin J Physiol*. 2010 Aug 31;53(4):234-44. (SCI)
2. Tseng KY, Chung MH, Sytwu HK, Lee HM, Chen KY, Chang C, Lin CK, Yen CH, **Chen JH**, Lin GJ, Ma HI, Yeh YS, Ju DT, Liu MY, Hueng DY. Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas. *J Neurooncol*. 2010 Nov;100(2):217-23. (SCI)
3. **Chen JH**, Kao WY, Chang PY, Dai MS, Chen YC, Chao TY, Ho CL. The Effect of Adding Rituximab to CHOP-based Therapy on Clinical Outcomes for Taiwanese Patients with Diffuse Large B-cell Lymphoma: A Retrospective Analysis in the Tri-Service General Hospital. *J Med Sci*
4. **Chen JH**, Kao WY, Chang PY, Dai MS, Chen YC, Chao TY, Ho CL. The Effect of Adding Rituximab to CHOP-based Therapy on Clinical Outcomes for Taiwanese Patients with Diffuse Large B-cell Lymphoma: A Retrospective Analysis in the Tri-Service General Hospital. *J Med Sci*. 2012 Oct 32(5):217-224. (SCI)
5. Hung SM, Yin T, Chen WC, Liu SC, **Chen JH**, Li SC, Chu DM. The effect of hospice combined care in Islands Hospital.
6. **Chen JH**, Huang TC, Chang PY, Dai MS, Ho CL, Chen YC, Chao TY, Kao WY. Malignant bowel obstruction from cancer: A retrospective clinical analysis. *Mol Clin Oncol*. 2014 Jan;2(1):13-18. (SCI)
7. **Chen JH**, Ho CL, Chen YC, Chao TY, Kao WY. Clinicopathological analysis and prognostic factors of 11 patients with primary non-Hodgkin lymphoma of the small intestine in a single institute *Oncol Lett*. 2014 Aug;8(2):876-880. (SCI)
8. Lu CS, Huang SH, Ho CL, **Chen JH**, Chao TY. Primary Neuroendocrine

- Carcinoma of the Breast. J BUON. 2014 Apr-Jun;19(2):419-29. (SCI)
9. Huang TC, **Chen JH**, Wu YY, Chang PY, Dai MS, Chao TY, Kao WY, Chen YC, Ho CL. The treatment outcome of multiple myeloma patients ineligible for hematopoietic transplantation--a single institutional experience in Taiwan. Ann Hematol. 2015 Jan;94(1):107-15. (SCI)
  10. **Chen JH**, Hsu SN, Huang TC, Wu YY, Lin C, Chang PY, Chen YC, Ho CL. Prognostic Significance of Initial Serum Albumin and 24 Hour Daily Protein Excretion Before Treatment in Multiple Myeloma. PLoS One. 2015 Jun 8;10(6):e0128905. (SCI)
  11. Wu YY, Chao TY, Liu HY, Huang TC, **Chen JH**, Dai MS, Janckila A, Lai SW, Chang PY. The correlation between a chronic inflammatory marker Tartrate-resistant acid phosphatase 5a with cancer cachexia. J BUON. 2015 Jan-Feb;20(1):325-31. (SCI)
  12. Ko KH, Hsu HH, Huang TW, Gao HW, Cheng CY, Hsu YC, Chang WC, Chu CM, **Chen JH**, Lee SC. Predictive Value of 18F-FDG PET and CT Morphologic Features for Recurrence in Pathological Stage IA Non-Small Cell Lung Cancer. Medicine (Baltimore). 2015 Jan;94(3). (SCI)
  13. Huang TC, Wu YY, Chen YG, Lai SW, Wu SC, Ye RH, Lu CS, **Chen JH**. Discrimination index of microcytic anemia in young soldiers: a single institutional analysis. PLoS One. 2015 Feb 13;10(2). (SCI)
  14. Ho CL, Lu CS, **Chen JH**, Chen YG, Huang TC, Wu YY. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era. Medicine (Baltimore). 2015 Jun; 94 (24):e993. (SCI)
  15. Lu CS, **Chen JH**, Huang TC, Wu YY, Chang PY, Dai MS, Chen YC, Ho CL. Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era. Leuk Lymphoma. 2015 Jul;56(7):2047-55. (SCI)
  16. Wu YY, Huang TC, Tsai TN, **Chen JH**, Dai MS, Chang PY, Ho CL, Ye RH, Chung TR, Chen YC, Chao TY. The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis. PLoS One. 2016 Mar 8;11(3):e0151112. (SCI)
  17. Huang IH, Wu YY, Huang TC, Chang WK, **Chen JH**. Statistics and outlook of primary hepatic angiosarcoma based on clinical stage. Oncol Lett. 2016 May;11(5):3218-3222. (SCI)

18. **Chen JH**, Chung CH, Wang YC, Hsu SN, Huang WY, Chien WC. Prevalence and Mortality-Related Factors of Multiple Myeloma in Taiwan. PLoS One. 2016 Dec 1;11(12):e0167227. (SCI)
19. Huang WY, Ho CL, Lee CC, Hsiao CW, Wu CC, Jao SW, Yang JF, Lo CH, **Chen JH**. Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer. PLoS One. 2017 Mar 22;12(3):e0174280. (SCI)
20. Wang YC, Chung CH, **Chen JH**, Chiang MH, Ti-Yin, Tsao CH, Lin FH, Chien WC, Shang ST, Chang FY. Gonorrhea infection increases the risk of prostate cancer in Asian population: a nationwide population-based cohort study. Eur J Clin Microbiol Infect Dis. 2017 May;36(5):813-821.
21. Chiu YH, Chung CH, Lin KT, Lin CS, **Chen JH**, Chen HC, Huang RY, Wu CT, Liu FC, Chien WC. Predictable biomarkers of developing lymphoma in patients with Sjögren syndrome: a nationwide population-based cohort study. Oncotarget. 2017 Jul 25;8(30):50098-50108.
22. **Chen JH**, Chen WL, Chan JY, Chen YW, Peng YJ, Cheng MF, Lin CS. Overexpression of CD164 in oral cavity squamous cell carcinoma predicts a favourable prognosis. Oncol Lett. 2017 Nov;14(5):6103-6108.
23. Chang CF, Chien WC, Chung CH, Lee JC, Hsu SN, **Chen JH**. Impact of hemodialysis on the prognosis of multiple myeloma: A nationwide population-based study and single-institute analysis. Oncol Lett. 2018 Aug;16(2):1991-2002.
24. Yang HC, Tsou HH, Pei SN, Chang CS, **Chen JH**, Yao M, Lin SJ, Lin J, Yuan Q, Xia N, Liu TW, Chen PJ, Cheng AL, Hsu C. Taiwan Cooperative Oncology Group. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. J Hepatol. 2018 Aug;69(2):286-292.
25. Lee CH, Lin C, Wang CY, Huang TC, Wu YY, Chien WC, **Chen JH**. Premorbid BMI as a prognostic factor in small-cell lung cancer-a single institute experience. Oncotarget. 2018 May 15;9(37):24642-24652.
26. Cho-Hao Lee, Tzu-Chuan Huang, Yung-Chih Wang, Yi-Ying Wu, Ching-Liang Ho, **Jia-Hong Chen**. The clinical outcome of brain metastases in nonsmall cell lung cancer patients with epidermal growth factor receptor mutation- A retrospective single-institution analysis. J Med Sci. 2018;38(6):247-251
27. **Chen JH**, Kuo KT, Bamodu OA, Lin YC, Yang RB, Yeh CT, Chao TY. Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and



- epithelial-to-mesenchymal transition. *Exp Cell Res.* 2018 Sep 15;370(2):444-453.
28. **Chen JH**, Wu Alexander TH, Tzeng David TW, Huang CC, Tzeng WM, Chao TY. Antrocin, a bioactive component from *Antrodia cinnamomea*, suppresses breast carcinogenesis and stemness via downregulation of  $\beta$ -catenin/ Notch1 /Akt signaling. *Phytomedicine.* 2019 Jan;52:70-78.
  29. Satriyo PB, Bamodu OA, Chen JH, Aryandono T, Haryana SM, Yeh CT, Chao TY. Cadherin 11 Inhibition Downregulates  $\beta$ -catenin, Deactivates the Canonical WNT Signalling Pathway and Suppresses the Cancer Stem Cell-Like Phenotype of Triple Negative Breast Cancer. *J Clin Med.* 2019 Jan 27;8(2).
  30. **Chen JH**, Huang WC, Bamodu OA, Chang PM, Chao TY, Huang TH. Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo. *BMC Cancer.* 2019 Jun 27;19(1):634.
  31. Liu WN, Chang CF, Chung CH, Chien WC, Huang TC, Wu YY, Ho CL, Chen JH. Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis. *PLoS One.* 2019 Sep 17;14(9):e0222522.
  32. **Chen JH**, Huang WY, Ho CL, Chao TY, Lee JC. Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma. *Head Neck.* 2019 Nov;41(11):3775-3782.
  33. **Chen JH**, Wu ATH, Bamodu OA, Yadav VK, Chao TY, Tzeng YM, Mukhopadhyay D, Hsiao M, Lee JC. Ovatodiolide Suppresses Oral Cancer Malignancy by Down-Regulating Exosomal Mir-21/STAT3/ $\beta$ -Catenin Cargo and Preventing Oncogenic Transformation of Normal Gingival Fibroblasts. *Cancers (Basel).* 2019 Dec 24;12(1).
  34. Lai SW, Bamodu OA, **Chen JH**, Wu AT, Lee WH, Chao TY, Yeh CT. Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer. *Cells.* 2020 Apr 8;9(4):911.
  35. Cheng CL, Huang SC, **Chen JH**, Wei CH, Fang WQ, Su TH, Yuan CT, Liu JH, Chuang MK, Tien HF. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era. *Oncologist.* 2020 Sep;25(9):793-802.
  36. Lee JC, Wu ATH, **Chen JH**, Huang WY, Lawal B, Mokgautsi N, Huang HS, Ho CL. HNC0014, a Multi-Targeted Small-Molecule, Inhibits Head and Neck

- Squamous Cell Carcinoma by Suppressing c-Met/STAT3/CD44/PD-L1 Oncoimmune Signature and Eliciting Antitumor Immune Responses. *Cancers* (Basel). 2020 Dec 14;12(12):3759.
37. Lawal B, Lin LC, Lee JC, **Chen JH**, Bekaii-Saab TS, Wu ATH, Ho CL. Multi-Omics Data Analysis of Gene Expressions and Alterations, Cancer-Associated Fibroblast and Immune Infiltrations, Reveals the Onco-Immune Prognostic Relevance of STAT3/CDK2/4/6 in Human Malignancies. *Cancers* (Basel). 2021 Feb 25;13(5):954.
  38. Chen PH, Wu YY, Lee CH, Chung CH, Chen YG, Huang TC, Yeh RH, Chang PY, Dai MS, Lai SW, Ho CL, **Chen JH**, Chen YC, Hu JM, Yang SS, Chien WC. Uracil-tegafur vs fluorouracil as postoperative adjuvant chemotherapy in Stage II and III colon cancer: A nationwide cohort study and meta-analysis. *Medicine* (Baltimore). 2021 May 7;100(18):e25756.
  39. **Chen JH**, Wu ATH, Lawal B, Tzeng DTW, Lee JC, Ho CL, Chao TY. Identification of Cancer Hub Gene Signatures Associated with Immune-Suppressive Tumor Microenvironment and Ovatodiolide as a Potential Cancer Immunotherapeutic Agent. *Cancers* (Basel). 2021 Jul 30;13(15):3847.
  40. Wu YY, Lai HF, Huang TC, Chen YG, Ye RH, Chang PY, Lai SW, Chen YC, Lee CH, Liu WN, Dai MS, **Chen JH**, Ho CL, Chiu YL. Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance. *Cell Death Dis.* 2021 Oct 5;12(10):908.
  41. Huang WY, Ho CL, Chao TY, Lee JC, **Chen JH**. Oral tegafur-uracil as a metronomic therapy in stage IVa and IVb cancer of the oral cavity. *Am J Otolaryngol.* Nov-Dec 2021;42(6):103156.
  42. Cheng SY, Wu ATH, Batiha GE, Ho CL, Lee JC, Lukman HY, Alorabi M, AlRasheedi AN, **Chen JH**. Identification of DPP4/CTNNB1/MET as a Theranostic Signature of Thyroid Cancer and Evaluation of the Therapeutic Potential of Sitagliptin. *Biology* (Basel). 2022 Feb 17;11(2):324.
  43. Kao CC, Ho CL, Yang MH, Tsai YT, Liu SY, Chang PY, Wu YY, **Chen JH**, Huang TC, Yehn RH, Dai MS, Chen YC, Sun GH, Cha TL. Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors. *J Clin Med.* 2022 Apr 14;11(8):2183.
  44. Chen PH, Jhou HJ, Chung CH, Wu YY, Huang TC, Lee CH, Chien WC, Chen JH. Benefit of Uracil-Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer. *Medicina* (Kaunas). 2022 Dec 20;59(1):10.
  45. Hsieh MS, Ling HH, Setiawan SA, Hardianti MS, Fong IH, Yeh CT, Chen JH. Therapeutic targeting of thioredoxin reductase 1 causes ferroptosis while

potentiating anti-PD-1 efficacy in head and neck cancer. *Chem Biol Interact.*  
2024 Apr 16;395:111004.

## **Speaker /Moderator Profile: Ching-Yao Yang**

### **Current Position**

Vice Director, Division of General Surgery,  
Department of Surgery, National Taiwan University Hospital

### **Education**

MD: College of Medicine, Taipei Medical University

PhD: Institute of Toxicology, College of Medicine, National Taiwan University

### **E-Mail**

cyang@ntuh.gov.tw

dtsurg15@gmail.com



### **Biography**

2024-now Vice Director, Division of General Surgery, Department of Surgery, National Taiwan University Hospital

2024-now Team Leader, Pancreas Surgery, Department of Surgery, National Taiwan University Hospital

2021-now Associate professor, Department of Surgery, College of Medicine, National Taiwan University

2015-2021 Assistant professor, Department of Surgery, College of Medicine, National Taiwan University

2011 PhD, Graduate Institute of Toxicology, College of Medicine, National Taiwan University (Lab of Molecular and Cancer Toxicology)

2007-now Attending surgeon, Division of General Surgery, Department of Surgery, NTUH

2002-2007 Attending surgeon, Department of Traumatology, NTUH

1997-2002 Residency, Department of Surgery, NTUH

1995 MD, graduated from Taipei Medical University

### **Professional interests and specialties**

1. MIS surgery on pancreas, spleen, and GIST.
2. Clinical and translational research on pancreatic cancer, PNETs, and GIST.

### **Selected Recent Publications**

1. Chiou LW, Chan CH, Jhuang YL, **Yang CY\***, Jeng YM\*. DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS<sup>G12C</sup>-mutant cancer. J Biomed Sci. 2023 Jun 29;30(1):50. (Corresponding author)
2. Chan CH, Chiou LW, Lee TY, Liu YR, Hsieh TH, **Yang CY\***, Jeng YM\*. PAK and PI3K pathway activation confers resistance to KRAS<sup>G12C</sup> inhibitor sotorasib. Br J Cancer. 2023 Jan;128(1):148-159. (Corresponding author)
3. Sasaki T, **Yang CY\***, Nakagawa K, Nagai M, Nishiwada S, Terai T, Sho M. Safety and Feasibility of Single-incision Laparoscopic Distal Pancreatectomy. Surg Laparosc Endosc Percutan Tech. 2022 Aug 1;32(4):488-493. (Corresponding author)
4. Li WT, Jeng YM, **Yang CY\***. Claudin-18 as a Marker for Identifying the Stomach and Pancreatobiliary Tract as the Primary Sites of Metastatic Adenocarcinoma. Am J Surg Pathol. 2020 Dec;44(12):1643-1648. (Corresponding author)

# 陳建華醫師

台北慈濟醫院胃腸肝膽科主任  
教育部部定慈濟大學助理教授  
台灣消化系內視鏡醫學會理事  
台灣介入性膽胰醫學會理事  
台北慈濟醫院胃腸科檢查室主任  
台北慈濟醫院預防醫學中心主任



# Curriculum Vitae

Name: 湯文誠

Sex: Male

Citizenship: Taiwan

Office Address & Tel. No.:

Department of Oncology, Chang Gung Memorial Hospital in Linkou, Chang-Gung Medical Foundation No.5, Fu-Hsing Street, Gueishan, Taoyuan, 333, Taiwan, R.O.C.

Tel: 03-3281200 #2517

Fax:

Cell Phone: 0978839114

E-mail: mtw111830@gamil.com

Language: Mandarin, English

Education:

長庚大學醫學系 2017 年畢業

Licenses:

腫瘤內科專科醫師

內科專科醫師

衛福部特管法 LDTs 核發檢測報告醫師學分證明

Employment Record:

2018/8~2019/7 林口長庚住院醫師

2019/9~2022/8 林口長庚內科住院醫師

2022/9~2024/8 林口長庚腫瘤科住院醫師

2024/9~now 林口長庚腫瘤科主治醫師

Professional Affiliations:

林口長庚醫院

## Bibliography:

### A. Publications

Tang WC, Huang PW, Lin CY, Hsieh CH, Hsu CL, Huang SF, *et al.*  
Cetuximab plus methotrexate in recurrent and/ or metastatic head-and-neck  
squamous cell carcinoma. J Cancer Res Pract 2023;10:101-9.

### B. Presentations

### C. Invited speaker

### D. Book

### E. References

## Award:

## Speaker Profile: Ming-Huang Chen

### Current Position


Director, Division of medical oncology, Department of  
Oncology, Taipei Veterans General Hospital

### Education

2002, Bachelor of Medicine, China Medical University, Taiwan

2013, Ph.D., Institute of Clinical Medicine, National Yang-Ming University, Taiwan

E-Mail: mhchen9@gmail.com



### Biography

Ming Huang-Chen is the Director of the Division of Medical Oncology in the Department of Oncology at Taipei Veterans General Hospital, Taiwan. With over 15 years of extensive clinical experience, he specializes in gastrointestinal tumors (esophageal cancer, gastric cancer, colorectal cancer, biliary tract cancer, and pancreatic cancer), and neuroendocrine tumors. He is also a clinical expert in the application of precision medicine and immunotherapy in cancer treatment. Beyond his clinical practice, Dr. Chen has a wealth of experience in investigator initiated trials (IIT) and publications. He actively contributes to teaching as a professor at National Yang-Ming Chiao-Tung University. He is widely recognized as an oncology precision expert and is frequently invited to share his expertise.

### **Professional interests and specialties**

Clinical Trials and GI cancer

### **Selected Recent Publications**

1. Chung SY, Chang YC, Hsu DS, Hung YC, Lu ML, Hung YP, Chiang NJ, Yeh CN, Hsiao M, Soong J, Su Y, **Chen MH**. A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer. *Neoplasia*. 2023 Jan; 35: 100856.

2. Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, Kitano M, Lee CK, Kim JW, **Chen MH**, Suksombooncharoen T, Ikeda M, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. *Lancet Gastroenterol Hepatol* 2024;29:S2468

3. Chiang NJ, Tan KT, Bai LY, Hsiao CF, Huang CY, Hung YP, Huang CJ, Chen SC, Shan YS, Chao Y, Huang YH, Lee IC, Lee PC, Su YY, Chen SJ, Yeh CN, Chen LT, **Chen MH**. Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. *Clin Cancer Res*. 2022 Oct 3; 28 (19): 4248-4257.